The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer
Open accessAbstract
Purpose: To determine the maximum-tolerated dose (MTD), toxicity, human antihuman antibody (HAHA) response, pharmacokinetics, organ dosimetry, targeting, and preliminary efficacy of yttrium-90–labeled anti–prostate-specific membrane antigen monoclonal antibody J591 (90 Y-J591) in patients with androgen-independent prostate cancer (PC). Patients and Methods: Patients with androgen-independent PC and evidence of disease progression received indium-111–J591 for pharmacokinetic and biodistribution determinations followed 1 week later by 90 Y-J591 at five dose levels: 5, 10, 15, 17.5, and 20 mCi/m 2. Patients were eligible for up to three re-treatments if platelet and neutrophil recovery was satisfactory. Results: Twenty-nine patients with androgen-independent PC received 90 Y-J591, four of whom were re-treated. Dose limiting toxicity (DLT) was seen at 20 mCi/m 2, with two patients experiencing thrombocytopenia with non–life-threatening bleeding episodes requiring platelet transfusions. The 17.5-mCi/m 2 dose level was determined to be the MTD. No re-treated patients experienced DLT. Nonhematologic toxicity was not dose limiting. Targeting of known sites of bone and soft tissue metastases was seen in the majority of patients. No HAHA response was seen. Antitumor activity was seen, with two patients experiencing 85% and 70% declines in prostate-specific antigen (PSA) levels lasting 8 and 8.6 months, respectively, before returning to baseline. Both patients had objective measurable disease responses. An additional six patients (21%) experienced PSA stabilization. Conclusion: The recommended dose for 90 Y-J591 is 17.5 mCi/m 2. Acceptable toxicity, excellent targeting of known sites of PC metastases, and biologic activity in patients with androgen-independent PC warrant further investigation of 90 Y-J591 in the treatment of patients with PC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
(1997) · PubMed · Cited by 1,541
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
Wright, G. L., Mayer Grob, B., Haley, C., Grossman, K., Newhall, K., Petrylak, D., Troyer, J., Konchuba, A., Schellhammer, P. F., & Moriarty, R. (1996) · Urology · doi:10.1016/s0090-4295(96)00184-7 · Cited by 635
Expression of the prostate-specific membrane antigen.
Israeli, R., Powell, C. T., Corr, J., Fair, W. R., & Heston, W. D. W. (1994) · PubMed · Cited by 601
Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A. K., Navarro, V., Knudsen, B., & Bander, N. H. (1997) · PubMed · Cited by 528
Self-citationConstitutive and antibody-induced internalization of prostate-specific membrane antigen.
Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., & Bander, N. H. (1998) · PubMed · Cited by 458
Self-citationProstate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells.
Pinto, J. T., Suffoletto, B. P., Berzin, T. M., Qiao, C. H., Lin, S., Tong, W. P., May, F., Mukherjee, B., & Heston, W. D. W. (1996) · PubMed · Cited by 389
Trover, J. K., Beckett, M. L., & Wright, G. L. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910620511 · Cited by 373
Carter, R. E., Feldman, A. R., & Coyle, J. T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.2.749 · Cited by 372
Cited by
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Eder, M., Schäfer, M., Bauder-Wüst, U., Hull, W.-E., Wängler, C., Mier, W., Haberkorn, U., & Eisenhut, M. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200279b · Cited by 843
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Bander, N. H., Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., & Goldsmith, S. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.160 · Cited by 509
Self-citationImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Tagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N. H., Osborne, J., Goldsmith, S. J., Larson, S., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
Self-citation
Metadata
- Authors
- Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-07-01
- Volume
- 22
- Issue
- 13
- Pages
- 2522-2531
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2107373757
- Cited by
- 313
- References
- 22
- FWCI
- 21.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer. https://app.cochat.ai/papers/10.1200/jco.2004.09.154
- The paper
- Milowsky, M. I., Nanus, D. M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S. J., & Bander, N. H. (2004). Phase I Trial of Yttrium-90—Labeled Anti—Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Androgen-Independent Prostate Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.09.154
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.